SGLT2 Inhibitor Luseogliflozin Improves Nonalcoholic Hepatosteatosis in a Rodent Model

被引：0
|
作者：
Fujishiro, Midori
Nakatsu, Yusuke
Sakoda, Hideyuki
Kushiyama, Akifumi
Asano, Tomoichiro
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2867-PO
引用
收藏
页码：A721 / A721
页数：1
相关论文
共 50 条
  • [1] Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    Shirong Qiang
    Yusuke Nakatsu
    Yasuyuki Seno
    Midori Fujishiro
    Hideyuki Sakoda
    Akifumi Kushiyama
    Keiichi Mori
    Yasuka Matsunaga
    Takeshi Yamamotoya
    Hideaki Kamata
    Tomoichiro Asano
    Diabetology & Metabolic Syndrome, 7
  • [2] Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    Qiang, Shirong
    Nakatsu, Yusuke
    Seno, Yasuyuki
    Fujishiro, Midori
    Sakoda, Hideyuki
    Kushiyama, Akifumi
    Mori, Keiichi
    Matsunaga, Yasuka
    Yamamotoya, Takeshi
    Kamata, Hideaki
    Asano, Tomoichiro
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [3] LUSEOGLIFLOZIN SGLT2 Inhibitor Treatment of Diabetes
    Tiwari, A.
    DRUGS OF THE FUTURE, 2012, 37 (09) : 637 - 643
  • [4] SGLT2 Inhibitor, Luseogliflozin, Prevent Sarcopenia by Improving Extracellular Lipidome
    Bamba, Ryo
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Senmaru, Takafumi
    Hamaguchi, Masahide
    Fukui, Michiaki
    DIABETES, 2021, 70
  • [5] Effects of a Novel SGLT2 Inhibitor Luseogliflozin on Intravaginal Bacteria and Fungi
    Kusunoki, Masataka
    Natsume, Yukie
    Sato, Daisuke
    Yamagishi, Yuka
    Suematsu, Hiroyuki
    Tsutsui, Hideyo
    Oshida, Yoshiharu
    Nakamura, Takao
    Mikamo, Hiroshige
    DIABETES, 2015, 64 : A331 - A331
  • [6] SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
    Tahara, Atsuo
    Takasu, Toshiyuki
    PHYSIOLOGICAL REPORTS, 2019, 7 (22):
  • [7] Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor
    Yamauchi, Keishi
    DIABETES, 2021, 70
  • [8] SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes
    Takiyama, Yumi
    Bessho, Ryoichi
    Maeda, Manami
    Atageldiyeva, Kuralay K.
    Yanagimachi, Tsuyoshi
    Honjo, Jun
    Fujita, Yukihiro
    Makino, Yuichi
    Haneda, Masakazu
    DIABETES, 2014, 63 : A136 - A136
  • [9] Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
    Kojima, Naoki
    Williams, Jan M.
    Takahashi, Teisuke
    Miyata, Noriyuki
    Roman, Richard J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (03): : 464 - 472
  • [10] Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study
    Samukawa, Yoshishige
    Sata, Michio
    Furihata, Kenichi
    Ito, Toshifumi
    Ueda, Naohiko
    Ochiai, Hidekazu
    Sakai, Soichi
    Kumagai, Yuji
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (05): : 439 - 447
12345